Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth?

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

On the clinical side, we saw GSK shell out just over $1 billion for ... Check out Fierce Biotech’s conference's kickoff coverage here for the full lowdown from Day 1, and go here for Fierce ...

However, the therapy would be the first-in-class available to treat tumours in this form. Unusually, GSK bought IDRX-42 based on very early ... which specialises in genetic sequencing, posted a strong ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...